About Venatorx Pharmaceuticals
Venatorx Pharmaceuticals is a private pharmaceutical company focused on antibiotics and antivirals.
61 articles about Venatorx Pharmaceuticals
VenatoRx Pharmaceuticals Expands Development Team as It Advances Its Antibacterial and Antiviral Portfolio
VenatoRx Pharmaceuticals today announced the addition of pharmaceutical industry veterans, Jennifer Ellis, Dr. Paul McGovern and Lauren P. Tornetta to its development team.
VenatoRx Pharmaceuticals today announced that it was named one of the “2019 Best Places to Work” in the Greater Philadelphia area by the Philadelphia Business Journal.
HHS, DoD, VenatoRx Pharmaceuticals to Co-Develop Novel Antibiotic to Treat Drug-Resistant Infections
CDC estimates that antibiotic-resistant infections affect at least two million people in the United States each year and drive $35 billion in healthcare system costs annually.
VenatoRx Pharmaceuticals Founders Named Entrepreneur Of The Year 2019 Award Winners in Greater Philadelphia
VenatoRx Pharmaceuticals today announced that its founders, Christopher J. Burns, Ph.D., Daniel C. Pevear, Ph.D., and Luigi Xerri, Ph.D., received the Entrepreneur Of The Year® 2019 Award in the Health and Life Sciences category in Greater Philadelphia.
VenatoRx Pharmaceuticals will present ten posters featuring its two development-stage products, cefepime/VNRX-5133 and ceftibuten/VNRX-7145, at ASM Microbe 2019 to be held June 20-24 in San Francisco, CA.
VenatoRx Pharmaceuticals to Present Data for its Injectable and Orally Bioavailable Beta-Lactamase Inhibitor Drug Candidates at ECCMID 2019
The 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held April 13-16, 2019 in Amsterdam, The Netherlands.
VenatoRx Pharmaceuticals today announced that Lisa Wittmer, Ph.D. has joined the Company as Chief Development Officer.
VenatoRx Pharmaceuticals to Present Orally Bioavailable Broad-Spectrum Beta-Lactamase Inhibitor for Superbugs at ACS National Meeting
VenatoRx Pharmaceuticals announced that its President and CEO, Christopher J. Burns, Ph.D., will present during the First Time Disclosure of Clinical Candidates at the American Chemical Society (ACS) National Meeting.
VenatoRx Pharmaceuticals’ Christopher J. Burns, Ph.D. Named CEO of the Year by Life Sciences Pennsylvania
Recognition honors a CEO who has demonstrated visionary leadership and active participation to advance the life sciences and biotech industry
VenatoRx Pharmaceuticals Awarded NIAID R01 Grant to Uncover Determinants of Gram-Negative Permeability
Leveraging a Unique Small Molecule Library, VenatoRx seeks to open challenging bottlenecks for antibacterial drug discovery and successfully introduce new antibacterial agents into the clinic
VenatoRx Pharmaceuticals, a world leader in antibacterial and antiviral drug research and development, announced that its Chief Business Officer, Tony Meehan, MBA, PhD, will present at the 2019 BIO CEO & Investor Conference.
VenatoRx Pharmaceuticals is a world leader in antibacterial and antiviral drug research and development. VenatoRx’s lead product, VNRX-5133, is an injectable beta-lactamase inhibitor (BLI) that features uniquely potent and selective activity against both serine- and metallo-beta-lactamases.
VenatoRx Pharmaceuticals to Present in vitro, in vivo and Phase I Data for cefepime/VNRX-5133 at IDWeek 2018
VenatoRx Pharmaceuticals will feature its lead clinical antibacterial candidate, cefepime/VNRX-5133, at IDWeek 2018 which is taking place in San Francisco, CA this week from October 3-7, 2018.
VenatoRx Pharmaceuticals announced that it was named one of the “2018 Best Places to Work” in the Greater Philadelphia area by the Philadelphia Business Journal.
VenatoRx Pharmaceuticals to present at ASM Microbe in the New Agents Discovery Summary Session and Emerging Tech Talks
The company will also present five posters featuring its lead clinical antibacterial candidate, cefepime/VNRX-5133
VenatoRx Pharmaceuticals announced that its President and CEO, Christopher J. Burns, Ph.D., will present at the UBS Global Healthcare Conference on Monday, May 21, 2018 at 8:00am ET in Ballroom V at the Grand Hyatt New York. The presentation will be webcast at www.venatorx.com/UBS2018.
Pipeline Corner Presentation, Mini Oral Sessions and Paper Poster Session to take place April 22-23
VenatoRx Pharmaceuticals to Present its Lead Clinical Antibacterial Candidate, VNRX-5133, at the American Chemical Society National Meeting
President and CEO, Christopher J. Burns, Ph.D., will present at the First-Time Disclosure of Clinical Candidates Oral Symposium on March 21, 2018 at 3:15pm CT
VenatoRx Pharmaceuticals Receives Award for up to $16 Million from DTRA to Develop a Novel, First-in-Class Antibiotic as Countermeasure against Potential Drug-Resistant Biodefense Category A/B Respiratory Pathogens
VenatoRx announced that it has been awarded up to $16 million from the Defense Threat Reduction Agency (DTRA), an agency of the U.S. Department of Defense.
VenatoRx Pharmaceuticals Receives FDA’s QIDP and Fast Track Designations for Development of Its Lead Antibiotic Program
The designations were granted for both complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).